Rigel Pharmaceuticals | RIGL - PE Price to Earnings


Rigel Pharmaceuticals reported 8.61 in PE Price to Earnings for its fiscal quarter ending in March of 2025.





Pe Change Date
Amgen 19.84 5.47 Mar/2026
Anika Therapeutics 47.54 27.2 Jun/2024
AstraZeneca 29.59 2.3 Mar/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Bristol-Myers Squibb 9.08 0.2 Mar/2026
Daiichi Sankyo 20.73 1.74 Dec/2025
Eli Lilly 40.27 0.06 Mar/2026
Halozyme Therapeutics 11.35 11.8 Mar/2026
Intrexon 7.54 221.44 Dec/2021
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Ligand Pharmaceuticals 56.5 26.8 Mar/2026
Neurocrine Biosciences 28.09 807.38 Mar/2026
Pfizer 9.32 5.16 Mar/2026
Regeneron Pharmaceuticals 25.14 7.03 Mar/2026
Rigel Pharmaceuticals 8.61 8.4 Mar/2025
Veracyte 24.89 20.41 Mar/2026